Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Head-and-neck squamous-cell cancer

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Threatened airway or major tumour haemorrhage

Stridor, inability to handle secretions, rapidly increasing work of breathing, expanding neck swelling or brisk oral or tracheostomy bleeding can precede complete obstruction or exsanguination.

Action: Call anaesthesia, ENT or maxillofacial surgery and major-haemorrhage support immediately, keep the patient upright with oxygen and suction, avoid sedation or supine transfer that may close a marginal airway and secure the airway or control bleeding in a theatre or interventional setting with a shared rescue plan.

Synopsis

Recognise persistent mucosal and neck-node presentations, protect the airway and nutrition, obtain diagnosis without compromising the neck, stage HPV- and site-specific disease and coordinate curative or palliative multidisciplinary treatment.

  • Persistent unexplained oral ulceration, unilateral throat symptoms, hoarseness, dysphagia, referred otalgia or adult neck lump requires urgent head-and-neck assessment; pain is not required.
  • First-line specialist assessment is full oral and neck examination plus flexible nasendoscopy; image and sample a suspicious node without proceeding to an unplanned open neck biopsy.
  • Ultrasound-guided fine-needle aspiration is often the first nodal sample; core biopsy is useful when cytology is non-diagnostic or lymphoma is possible.
  • The diagnostic reference standard is adequate histology from the primary or metastatic node, with p16 testing for oropharyngeal squamous cancer and other site-directed viral testing when appropriate.
  • Contrast CT or MRI defines local and nodal anatomy; PET-CT is used for selected advanced staging, an occult primary and post-chemoradiotherapy response assessment.
  • Do not begin treatment before airway, dental, nutrition, speech-and-language, hearing, renal, performance and psychosocial assessment have been integrated by the specialist MDT.
  • Early disease may be treated with one modality, usually transoral or open surgery or radiotherapy; locally advanced disease commonly needs surgery plus risk-adapted adjuvant therapy or definitive chemoradiotherapy.
  • Cisplatin is a key radiosensitiser for eligible patients, but renal impairment, hearing loss, neuropathy and frailty may make another regimen or radiotherapy alone safer.
  • HPV-positive oropharyngeal cancer has a better average prognosis, but smoking history, anatomical stage and patient factors still matter and HPV status does not justify off-protocol de-escalation.
  • Rehabilitation, smoking and alcohol support, oral care, swallowing exercises and late-effect surveillance are components of cancer treatment, not optional extras.

Key red flags

Stridor, drooling, tripod posture, cyanosis, exhaustion or reduced consciousness indicates critical upper-airway obstruction.

Persistent unexplained neck lump, oral ulcer, unilateral throat pain, dysphagia, odynophagia, hoarseness or referred otalgia requires urgent cancer assessment.

A pulsatile sentinel bleed from mouth, neck wound or tracheostomy can precede carotid blowout and needs immediate specialist haemorrhage planning.

Trismus, cranial-nerve deficit, Horner syndrome, fixed nodal disease or severe deep pain suggests skull-base, neural or carotid-space invasion.

Weight loss, dehydration, aspiration, recurrent chest infection or inability to swallow medication requires same-day nutritional and airway assessment.

Airway or bleeding emergency

Stridor, secretion intolerance, rapid respiratory fatigue or sentinel tumour bleeding requires immediate multidisciplinary rescue rather than routine clinic investigation.

Investigation priorities

01
First-line examination and flexible nasendoscopyFirst stepFirst line

Inspect all accessible mucosa, vocal-cord movement and the upper airway and identify a primary or synchronous lesion.

02
First-line ultrasound-guided nodal samplingFirst line

Obtain cytology from a suspicious cervical node while defining its solid, cystic and vascular features.

Management branches

Urgent presentationProtect airway and circulation first

The patient has stridor, secretion intolerance, respiratory fatigue, expanding swelling or major bleeding.

  1. Call senior anaesthesia and head-and-neck surgical teams and move to a monitored area while keeping the patient upright, calm and oxygenated with suction available.
  2. Agree a primary airway or haemorrhage plan and a failed-plan rescue before sedation, transfer or instrumentation; use theatre and interventional radiology support where indicated.
  3. After physiological control, obtain targeted imaging and biopsy without delaying definitive airway, embolisation, surgery, antibiotics or transfusion required for the emergency.

Key medicines

Cisplatin with radiotherapyA common definitive or postoperative radiosensitising protocol gives cisplatin 100 mg/m² intravenously on radiotherapy days 1, 22 and 43; some specialist protocols use 40 mg/m² weekly. Use the exact local regimen and eligibility criteria.Provide protocol hydration and antiemesis and monitor creatinine clearance, magnesium, marrow, hearing, neuropathy and performance; do not casually substitute schedules or continue through clinically important renal or auditory toxicity.
PembrolizumabUse the licensed fixed intravenous schedule, commonly 200 mg every 3 weeks or 400 mg every 6 weeks, alone or with protocol chemotherapy only when the recurrent or metastatic indication and current NICE biomarker criteria are met.Check prior transplant and autoimmune disease and monitor for pneumonitis, colitis, hepatitis, nephritis, myocarditis and endocrine or neurological toxicity; new deterioration requires infection and progression assessment as well as immune-toxicity treatment.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG36 head and neck cancerAssessment, diagnosis, staging, treatment, rehabilitation and follow-up.
  • NICE NG12 suspected cancer recognition and referralUrgent referral features for oral, laryngeal and neck presentations.
  • BNF cisplatinUK dosing principles, contraindications, adverse effects and monitoring.
  • Pembrolizumab Summary of Product CharacteristicsLicensed schedule and immune-mediated toxicity management.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom